202 related articles for article (PubMed ID: 33116240)
21. High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications.
Lionetti M; Fabris S; Cutrona G; Agnelli L; Ciardullo C; Matis S; Ciceri G; Colombo M; Maura F; Mosca L; Gentile M; Recchia AG; Ilariucci F; Musolino C; Molica S; Di Raimondo F; Cortelezzi A; Rossi D; Gaidano G; Morabito F; Ferrarini M; Neri A
Br J Haematol; 2014 Jun; 165(5):629-39. PubMed ID: 24579978
[TBL] [Abstract][Full Text] [Related]
22. TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations.
Zenz T; Vollmer D; Trbusek M; Smardova J; Benner A; Soussi T; Helfrich H; Heuberger M; Hoth P; Fuge M; Denzel T; Häbe S; Malcikova J; Kuglik P; Truong S; Patten N; Wu L; Oscier D; Ibbotson R; Gardiner A; Tracy I; Lin K; Pettitt A; Pospisilova S; Mayer J; Hallek M; Döhner H; Stilgenbauer S;
Leukemia; 2010 Dec; 24(12):2072-9. PubMed ID: 20861914
[TBL] [Abstract][Full Text] [Related]
23. Relevance of TP53 for CLL diagnostics.
Catherwood MA; Gonzalez D; Donaldson D; Clifford R; Mills K; Thornton P
J Clin Pathol; 2019 May; 72(5):343-346. PubMed ID: 30712002
[No Abstract] [Full Text] [Related]
24.
Catherwood MA; Wren D; Chiecchio L; Cavalieri D; Donaldson D; Lawless S; ElHassadi E; Hayat A; Cahill MR; O'Shea D; Sargent J; Stewart P; Maurya M; Quinn J; Murphy P; de Castro DG; Mills K; Cross NCP; Forconi F; Iyengar S; Schuh A; Thornton P
Front Oncol; 2022; 12():909615. PubMed ID: 35837095
[TBL] [Abstract][Full Text] [Related]
25. [TP53 mutation analysis in chronic lymphocytic leukaemia].
Fésüs V; Marosvári D; Kajtár B; Király PA; Demeter J; Gurbity Pálfi T; Egyed M; Plander M; Farkas P; Mátrai Z; Matolcsy A; Bödör C
Orv Hetil; 2017 Feb; 158(6):220-228. PubMed ID: 28166664
[TBL] [Abstract][Full Text] [Related]
26. THE SPECTRUM OF TP53, SF3B1, AND NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPOSED TO IONIZING RADIATION DUE TO THE CHORNOBYL NPP ACCIDENT.
Bilous NI; Abramenko IV; Chumak AA; Dyagil IS; Martina ZV; Saenko V; Bazyka DA
Probl Radiac Med Radiobiol; 2018 Dec; 23():283-301. PubMed ID: 30582853
[TBL] [Abstract][Full Text] [Related]
27.
Campo E; Cymbalista F; Ghia P; Jäger U; Pospisilova S; Rosenquist R; Schuh A; Stilgenbauer S
Haematologica; 2018 Dec; 103(12):1956-1968. PubMed ID: 30442727
[TBL] [Abstract][Full Text] [Related]
28. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.
Stilgenbauer S; Schnaiter A; Paschka P; Zenz T; Rossi M; Döhner K; Bühler A; Böttcher S; Ritgen M; Kneba M; Winkler D; Tausch E; Hoth P; Edelmann J; Mertens D; Bullinger L; Bergmann M; Kless S; Mack S; Jäger U; Patten N; Wu L; Wenger MK; Fingerle-Rowson G; Lichter P; Cazzola M; Wendtner CM; Fink AM; Fischer K; Busch R; Hallek M; Döhner H
Blood; 2014 May; 123(21):3247-54. PubMed ID: 24652989
[TBL] [Abstract][Full Text] [Related]
29. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
Le Bris Y; Struski S; Guièze R; Rouvellat C; Prade N; Troussard X; Tournilhac O; Béné MC; Delabesse E; Ysebaert L
Hematol Oncol; 2017 Dec; 35(4):664-670. PubMed ID: 27678008
[TBL] [Abstract][Full Text] [Related]
30. Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia.
Fabris S; Mosca L; Todoerti K; Cutrona G; Lionetti M; Intini D; Matis S; Colombo M; Agnelli L; Gentile M; Spriano M; Callea V; Festini G; Molica S; Lambertenghi Deliliers G; Morabito F; Ferrarini M; Neri A
Genes Chromosomes Cancer; 2008 Sep; 47(9):781-93. PubMed ID: 18521849
[TBL] [Abstract][Full Text] [Related]
31. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data.
International CLL-IPI working group
Lancet Oncol; 2016 Jun; 17(6):779-790. PubMed ID: 27185642
[TBL] [Abstract][Full Text] [Related]
32. Improving risk-stratification of patients with chronic lymphocytic leukemia using multivariate patient similarity networks.
Turcsanyi P; Kriegova E; Kudelka M; Radvansky M; Kruzova L; Urbanova R; Schneiderova P; Urbankova H; Papajik T
Leuk Res; 2019 Apr; 79():60-68. PubMed ID: 30852300
[TBL] [Abstract][Full Text] [Related]
33. TP53 mutation and survival in chronic lymphocytic leukemia.
Zenz T; Eichhorst B; Busch R; Denzel T; Häbe S; Winkler D; Bühler A; Edelmann J; Bergmann M; Hopfinger G; Hensel M; Hallek M; Döhner H; Stilgenbauer S
J Clin Oncol; 2010 Oct; 28(29):4473-9. PubMed ID: 20697090
[TBL] [Abstract][Full Text] [Related]
34. Chronic lymphocytic leukemia with isochromosome 17q: An aggressive subgroup associated with TP53 mutations and complex karyotypes.
Collado R; Puiggros A; López-Guerrero JA; Calasanz MJ; Larráyoz MJ; Ivars D; García-Casado Z; Abella E; Orero MT; Talavera E; Oliveira AC; Hernández-Rivas JM; Hernández-Sánchez M; Luño E; Valiente A; Grau J; Portal I; Gardella S; Salgado AC; Giménez MT; Ardanaz MT; Campeny A; Hernández JJ; Álvarez S; Espinet B; Carbonell F
Cancer Lett; 2017 Nov; 409():42-48. PubMed ID: 28888994
[TBL] [Abstract][Full Text] [Related]
35. Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.
Bühler A; Wendtner CM; Kipps TJ; Rassenti L; Fraser GA; Michallet AS; Hillmen P; Dürig J; Gregory SA; Kalaycio M; Aurran-Schleinitz T; Trentin L; Gribben JG; Chanan-Khan A; Purse B; Zhang J; De Bedout S; Mei J; Hallek M; Stilgenbauer S
Blood Cancer J; 2016 Mar; 6(3):e404. PubMed ID: 26967821
[TBL] [Abstract][Full Text] [Related]
36. Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.
Xia Y; Fan L; Wang L; Gale RP; Wang M; Tian T; Wu W; Yu L; Chen YY; Xu W; Li JY
Oncotarget; 2015 Mar; 6(7):5426-34. PubMed ID: 25605254
[TBL] [Abstract][Full Text] [Related]
37. Frequency Of TP53 Gene Mutation In Patients With Chronic Lymphocytic Leukaemia.
Qadir H; Nasir N; Qadir N; Adil SN; Tanzeem H; Qadir A
J Ayub Med Coll Abbottabad; 2020; 32(4):523-526. PubMed ID: 33225656
[TBL] [Abstract][Full Text] [Related]
38. Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.
Pozzo F; Dal Bo M; Peragine N; Bomben R; Zucchetto A; Rossi F; Degan M; Rossi D; Chiarenza A; Grossi A; Di Raimondo F; Zaja F; Pozzato G; Secchiero P; Gaidano G; Del Poeta G; Zauli G; Fo À R; Guarini A; Gattei V
J Hematol Oncol; 2013 Nov; 6():83. PubMed ID: 24283248
[TBL] [Abstract][Full Text] [Related]
39. A new genetic abnormality leading to TP53 gene deletion in chronic lymphocytic leukaemia.
López C; Baumann T; Costa D; López-Guerra M; Navarro A; Gómez C; Arias A; Muñoz C; Rozman M; Villamor N; Colomer D; Montserrat E; Campo E; Carrió A
Br J Haematol; 2012 Mar; 156(5):612-8. PubMed ID: 22150335
[TBL] [Abstract][Full Text] [Related]
40. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.
Hallek M
Am J Hematol; 2019 Nov; 94(11):1266-1287. PubMed ID: 31364186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
